Kajdácsi, Erika
Balla, Zsuzsanna
Pólai, Zsófia
Cervenak, László
Farkas, Henriette
Funding for this research was provided by:
National Research, Development and Innovation Office (K124557)
Semmelweis University
Article History
Received: 3 February 2023
Accepted: 10 August 2023
First Online: 17 August 2023
Competing interests
: Henriette Farkas has received research grants from CSL Behring, Shire/Takeda and Pharming, and served as an advisor for these companies as well as Biocryst, ONO Pharmaceutical, Austria. Henriette Farkas has participated in clinical trials/registries for BioCryst, CSL Behring, Pharming, Kalvista and Shire/Takeda. The other authors declare no conflict of interest.